正在加载公司
Just reported
Q4 FY2026 results
From Cencora's results release of 2026年11月4日. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
US$88.35B
+5.5% y/y
+4.2% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$2.71
-31% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$906.8M
-19% q/q
Guided
—
No guide given
Company outlook
Full year 2027
- EPS, adjustedUS$19.40 – US$19.75First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Cencora is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A
基于 Cencora, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
